Evidence map›Paper›PMID 34298691›Full record

ArticleCancers2021

CSNK1A1, KDM2A, and LTB4R2 Are New Druggable Vulnerabilities in Lung Cancer.

Elisabetta Sauta, Francesca Reggiani, Federica Torricelli, Eleonora Zanetti, Elena Tagliavini, Giacomo Santandrea, Giulia Gobbi, Silvia Strocchi, Massimiliano Paci, Giovanna Damia and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. SP1 undergoes phase separation and activates RGS20 expression through super-enhancers to promote lung adenocarcinoma progression.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Elisabetta SautaLaboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy.ORCID 0000-0002-7830-988X
Francesca ReggianiLaboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy.ORCID 0000-0002-4090-8908
Federica TorricelliLaboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy.
Eleonora ZanettiPathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy.ORCID 0000-0002-3483-130X
Elena TagliaviniPathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy.
Giacomo SantandreaPathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy.ORCID 0000-0001-5487-0683
Giulia GobbiLaboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy.
Silvia StrocchiLaboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy.ORCID 0000-0003-1248-4498
Massimiliano PaciThoracic Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy.
Giovanna DamiaLaboratory of Molecular Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy.ORCID 0000-0001-9749-434X
Riccardo BellazziDepartment of Electrical, Computer and Biomedical Engineering, University of Pavia, 27100 Pavia, Italy.
Davide AmbrosettiDepartment of Pharmacy and Biotechnology (FaBit), University of Bologna, 40126 Bologna, Italy.
Alessia CiarrocchiLaboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy.ORCID 0000-0002-5541-2075
Valentina SancisiLaboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy.ORCID 0000-0003-4357-1228
Azienda Sanitaria Unità Locale di Reggio Emilia · ITUniversity of Pavia · ITMario Negri Institute for Pharmacological Research · ITUniversity of Bologna · ITUniversity of Modena and Reggio Emilia · IT

Funding

Fondazione Umberto Veronesi FellowshipMinistero della Salute Bando per la Valorizzazione della Ricerca in ambito oncologico 2018 - Fondi 5 per Mille 2016Ministero della Salute Bando per la Valorizzazione della Ricerca in ambito oncologico 2019 - Fondi 5 per Mille 2017
6 · The paper itself

Abstract

Lung cancer is the leading cause of cancer-related human death. It is a heterogeneous disease, classified in two main histotypes, small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC), which is further subdivided into squamous-cell carcinoma (SCC) and adenocarcinoma (AD) subtypes. Despite the introduction of innovative therapeutics, mainly designed to specifically treat AD patients, the prognosis of lung cancer remains poor. In particular, available treatments for SCLC and SCC patients are currently limited to platinum-based chemotherapy and immune checkpoint inhibitors. In this work, we used an integrative approach to identify novel vulnerabilities in lung cancer. First, we compared the data from a CRISPR/Cas9 dependency screening performed in our laboratory with Cancer Dependency Map Project data, essentiality comprising information on 73 lung cancer cell lines. Next, to identify relevant therapeutic targets, we integrated dependency data with pharmacological data and TCGA gene expression information. Through this analysis, we identified CSNK1A1, KDM2A, and LTB4R2 as relevant druggable essentiality genes in lung cancer. We validated the antiproliferative effect of genetic or pharmacological inhibition of these genes in two lung cancer cell lines. Overall, our results identified new vulnerabilities associated with different lung cancer histotypes, laying the basis for the development of new therapeutic strategies.

Indexed as

CRISPR/Cas9 screeningCSNK1A1KDM2ALTB4R2lung cancer

Identifiers

PMID34298691
PMCPMC8305418
OpenAlexW3179676302

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.